Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Oct;40(4):404–406. doi: 10.1111/j.1365-2125.1995.tb04564.x

The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers.

J Roberts 1, D G Waller 1, N O'Shea 1, B S Macklin 1, A G Renwick 1
PMCID: PMC1365161  PMID: 8554944

Abstract

The plasma pharmacokinetics of levodopa were studied in eight healthy young subjects following an i.v. infusion of 50 mg over 5 min. Subjects were studied on two occasions in random order following treatment with carbidopa; on one occasion they were pretreated with selegiline (four doses of 10 mg over the preceding 3 days) and on the other with a placebo. The mean plasma concentration-time curves on each occasion were essentially superimposable and there were no significant differences in any calculated pharmacokinetic parameter. Selegiline does not significantly alter the distribution or elimination of levodopa from plasma.

Full text

PDF
404

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baraczka K., Fekete M. I., Kanyicska B. Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration. J Neural Transm. 1983;58(3-4):299–304. doi: 10.1007/BF01252815. [DOI] [PubMed] [Google Scholar]
  2. Baronti F., Davis T. L., Boldry R. C., Mouradian M. M., Chase T. N. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology. 1992 Mar;42(3 Pt 1):541–544. doi: 10.1212/wnl.42.3.541. [DOI] [PubMed] [Google Scholar]
  3. Cedarbaum J. M., Silvestri M., Clark M., Harts A., Kutt H. L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease. Clin Neuropharmacol. 1990 Feb;13(1):29–35. doi: 10.1097/00002826-199002000-00003. [DOI] [PubMed] [Google Scholar]
  4. Evans M. A., Broe G. A., Triggs E. J., Cheung M., Creasey H., Paull P. D. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology. 1981 Oct;31(10):1288–1294. doi: 10.1212/wnl.31.10.1288. [DOI] [PubMed] [Google Scholar]
  5. Heinonen E. H., Rinne U. K., Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand Suppl. 1989;126:113–118. doi: 10.1111/j.1600-0404.1989.tb01790.x. [DOI] [PubMed] [Google Scholar]
  6. Hubble J. P., Koller W. C., Waters C. Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clin Neuropharmacol. 1993 Feb;16(1):83–87. doi: 10.1097/00002826-199302000-00010. [DOI] [PubMed] [Google Scholar]
  7. Kaakkola S., Teräväinen H., Ahtila S., Rita H., Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology. 1994 Jan;44(1):77–80. doi: 10.1212/wnl.44.1.77. [DOI] [PubMed] [Google Scholar]
  8. Keränen T., Gordin A., Harjola V. P., Karlsson M., Korpela K., Pentikäinen P. J., Rita H., Seppälä L., Wikberg T. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol. 1993 Apr;16(2):145–156. doi: 10.1097/00002826-199304000-00007. [DOI] [PubMed] [Google Scholar]
  9. Knoll J. Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. Med Res Rev. 1992 Sep;12(5):505–524. doi: 10.1002/med.2610120504. [DOI] [PubMed] [Google Scholar]
  10. Lieberman A., Fazzini E. Experience with selegiline and levodopa in advanced Parkinson's disease. Acta Neurol Scand Suppl. 1991;136:66–69. doi: 10.1111/j.1600-0404.1991.tb05022.x. [DOI] [PubMed] [Google Scholar]
  11. Myllylä V. V., Sotaniemi K. A., Vuorinen J. A., Heinonen E. H. Selegiline in de novo parkinsonian patients: the Finnish study. Mov Disord. 1993;8 (Suppl 1):S41–S44. doi: 10.1002/mds.870080509. [DOI] [PubMed] [Google Scholar]
  12. Nguyen T. B., Angers M. Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain. Biochem Pharmacol. 1987 May 15;36(10):1731–1735. doi: 10.1016/0006-2952(87)90060-8. [DOI] [PubMed] [Google Scholar]
  13. Nutt J. G. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol. 1987 Oct;22(4):535–540. doi: 10.1002/ana.410220415. [DOI] [PubMed] [Google Scholar]
  14. Robertson D. R., Renwick A. G., Wood N. D., Cross N., Macklin B. S., Fleming J. S., Waller D. G., George C. F. The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol. 1990 Jan;29(1):47–53. doi: 10.1111/j.1365-2125.1990.tb03601.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Robertson D. R., Wood N. D., Everest H., Monks K., Waller D. G., Renwick A. G., George C. F. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol. 1989 Jul;28(1):61–69. doi: 10.1111/j.1365-2125.1989.tb03506.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Takahashi M., Yuasa R., Imai T., Tachibana H., Yorifuji S., Nakamura Y., Ogawa N. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial. Intern Med. 1994 Sep;33(9):517–524. doi: 10.2169/internalmedicine.33.517. [DOI] [PubMed] [Google Scholar]
  17. Wade D. N., Mearrick P. T., Birkett D. J., Morris J. Variability of L-dopa absorption in man. Aust N Z J Med. 1974 Apr;4(2):138–143. doi: 10.1111/j.1445-5994.1974.tb03162.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES